Corcept医疗

Corcept Therapeutics CORT: Guyer William buys and sells 11,767 shares on 2026-03-20.

Corcept Therapeutics Sees Bullish Signals with KDJ Golden Cross and Marubozu Pattern

Corcept Therapeutics: 15min chart shows RSI Oversold, KDJ Golden Cross

Corcept Therapeutics

Corcept Therapeutics Stock Soars After $3M Insider Purchase

Insperity

Insider Buying Report Highlights NSP and CORT Purchases

Catalyst<ul> <li>Fund flow data shows overall positive trends with large and extra-large order inflows supporting CORT.</li></ul>Risk<ul> <li>Technical indicators show a weak market state with bearish signals dominant over the last month.</li> <li>Fundamental analysis highlights negative factors such as high asset-market value and PB-ROE imbalances, raising valuation concerns.</li></ul>

Key Factors

Corcept Therapeutics faces a securities fraud lawsuit alleging it misled investors by failing to disclose the FDA's concerns about the adequacy of clinical evidence for relacorilant's New Drug Application.The FDA reportedly warned Corcept that significant issues would arise with the NDA review if submitted, according to the lawsuit.Corcept's Chief Development Officer Guyer William bought and sold 11,767 shares of CORT on March 20, 2026, at prices of $21.65 and $36.01 per share respectively.

Recent Updates

CORT News